In 1991, Sahin et al. reported the first documented case of plasmacytoid urothelial carcinoma (PUC). A rare and highly aggressive subtype that was recently incorporated into the WHO classification of urothelial carcinomas, representing 1-3% of cases of bladder cancers. The tumor cells are characterized by eccentrically placed nuclei with abundant eosinophilic cytoplasm and demonstrate positive immunostaining for CD138, and this variant is generally linked to an unfavorable prognosis. In this article, we present the case of a 61-year-old male diagnosed with PUC managed with concurrent chemoradiotherapy.
Bouayed et al. (Sun,) studied this question.